IMRN Stock Analysis: Buy, Sell, or Hold?
IMRN - Immuron Limited American Depositary Shares
$1.12
-0.06 (-5.08%)
âŧ
5d:
+1.82%
30d:
-4.27%
90d:
+14.29%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 27, 2026
2d
Get Alerted When IMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IMRN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IMRN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: IMRN is currently trading at $1.12, which is considered fair relative to its 30-day fair value range of $1.07 to $1.16.
Technical Outlook: Technically, IMRN is in a uptrend. Immediate support is located at $1.03, while resistance sits at $1.22. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: IMRN scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+257.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMRN is in a uptrend. Immediate support is located at $1.03, while resistance sits at $1.22. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: IMRN scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+257.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.07 -
$1.16
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 257.5% below Wall St target ($4.00)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.07 -
$1.16
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.03
Resistance Level
$1.22
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-74.17
Wall Street Target
$4.00
(+257.5%)
Revenue Growth (YoY)
4.8%
Profit Margin
-62.1%
Share & Embed Analysis
Last updated: August 24, 2026 1:38 AM ET
Data refreshes hourly during market hours. Next update: 2:38 AM
Data refreshes hourly during market hours. Next update: 2:38 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
